

National Ataxia Foundation Research Grant

Grantor: National Ataxia Foundation

Closes: 7/15/2010

Maximum: \$30,000.00

National Ataxia Foundation Research Grant

Letter of Intent Due Date: July 15, 2010

Application due: August 15, 2010

In its continuing efforts to find the cause, treatment, and cure for the ataxias, the National Ataxia Foundation (NAF) provides limited, short-term financial support of ataxia research.

NAF research grants are for new and innovative studies that are relevant to the cause, pathogenesis or treatment of the hereditary or sporadic ataxias.

Due to the larger availability of funding for Ataxia- Telangiectasia (A-T), those research proposals will receive a lower priority. However, a higher ranking will be given to those Ataxia-Telangiectasia research studies which lend themselves to an overall better understanding of the ataxia process.

Research grants are offered primarily as “seed monies” to assist investigators in the early or pilot phase of their studies and as additional support for ongoing investigations on demonstration of need. It is hoped that these studies will be further developed to attract future funding from other sources. Grants are awarded for one year only. If funding for a second year is desired then another grant application should be submitted for that funding period.

The average funds granted will be up to \$15,000 but funding may be considered for up to \$30,000 for projects deserving special consideration.

National Ataxia Foundation
2600 Fernbrook Lane Suite 119
Minneapolis, MN 55447-4752

Phone: (763)553-0020

Fax: (763) 553-0167

E-Mail: naf@ataxia.org

Link: <http://www.ataxia.org/research/ataxia-research-grants.aspx>

Categories: Ataxia , Brain, Brain Disorders, Clinical Research, Disease-Specific Research, Inheritable Disorders, Motor Disorders, Movement Disorders, Muscle Disorders, Musculoskeletal Conditions, Neurodegenerative, Neurology, Neuromuscular, Neuropathology, Neuroscience, Pathogenesis , Pilot Studies, Rare Disorders, Seed Money/Seed Grant

Audience: Neurologist, Neuroscientist, Physician Researcher